|Bid||0.1450 x N/A|
|Ask||0.1500 x N/A|
|Day's Range||0.1500 - 0.1700|
|52 Week Range||0.1400 - 0.2800|
|Beta (5Y Monthly)||0.40|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.00|
LONDON and ONTARIO, California, Oct. 24, 2019 /CNW/ -- Sernova Corp. (TSX-V:SVA.V - News) (OTCQB:SEOVF - News) (FSE:PSH.F - News), a clinical-stage regenerative medicine company, is pleased to announce that Mr. David Swetlow, CPA, CA, has joined Sernova as Chief Financial Officer. Mr. Swetlow is a veteran of the high tech and life sciences industries with over 20 years in various senior management, board, and advisory roles for start-up, acceleration, and high-growth stage companies, including multiple TSX and Nasdaq listed biotech companies amongst them QLT Inc. and Protox Therapeutics Inc. Adding a full-time CFO at this inflection point for the company with our recent announcement of initial positive early efficacy indicators for our Cell Pouch(TM) Phase I/II US clinical trial for type-1 diabetes and ongoing business development activities will accelerate execution of the company's financial, business and capital markets goals and strategies," said Dr. Philip Toleikis, President and CEO of Sernova.
Vancouver, British Columbia--(Newsfile Corp. - October 17, 2019) - Sernova Corp. (TSXV: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical stage regenerative medicine company, has reported findings that further validate Cell Pouch™ and therapeutic cell performance in Type-1 diabetes. The Cell Pouch™ is a novel implantable device, that is transplanted with therapeutic cells such as insulin producing islets. InvestmentPitch Media has produced a "video" which describes this news. If this link is not enabled, please ...
Sernova Corp. (CVE:SVA) shareholders will doubtless be very grateful to see the share price up 42% in the last...